BRCA Gene Mutations and Prostate Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F23%3A10158493" target="_blank" >RIV/00098892:_____/23:10158493 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/23:73616229
Result on the web
<a href="https://www.intechopen.com/chapters/85044" target="_blank" >https://www.intechopen.com/chapters/85044</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5772/intechopen.108792" target="_blank" >10.5772/intechopen.108792</a>
Alternative languages
Result language
angličtina
Original language name
BRCA Gene Mutations and Prostate Cancer
Original language description
Prostate cancer remains the second most common cancer in men, with diverse courses from indolent cases to aggressive diseases. Among the key factors implicated in its pathogenesis are genomic alterations such as the TMPRSS2-ERG and related fusion oncogenes, loss of tumor suppressor PTEN, p53 or NKX3.1, inflammation, enhanced DNA damage, and chromosomal instability. Men with prostate cancer who carry BRCA1/2 mutations are at more risk of worse disease and poor prognosis. Cancer cells with mutant BRCA1 or BRCA2 repair genes with defects in homologous recombination are vulnerable to PARP inhibitors that target the genetic phenomenon known as synthetic lethality to exploit faulty DNA repair mechanisms. With relevance to prostate cancer, other features of cancer cells may also sensitize to PARP inhibitors, including aberrant transcription due to the androgen-driven fusion oncogene TMPRSS2-ERG or PTEN loss. Several models of synthetic lethality and potential biomarkers suggested up to date are also discussed. The chapter also highlights the importance of genetic screening of men with BRCA and shows diagnostic utility of plasma-derived circulating tumor DNA.
Czech name
—
Czech description
—
Classification
Type
C - Chapter in a specialist book
CEP classification
—
OECD FORD branch
30109 - Pathology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Book/collection name
BRCA1 and BRCA2 Mutations : Diagnostic and Therapeutic Implications
ISBN
978-1-80356-806-5
Number of pages of the result
9
Pages from-to
nestrankovano
Number of pages of the book
134
Publisher name
IntechOpen Limited
Place of publication
London
UT code for WoS chapter
—